Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $34 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences launches Caris ChromoSeq tumor profiling assay
- Caris Life Sciences initiated with a Buy at Goldman Sachs
- Caris Life Sciences announces finalized Achieve 1 Study results
- Caris Life Sciences announces publication of study on GPSai algorithm
- Caris Life Sciences introduces new Caris AI Insights